RxDoctor Payments Data

Mark Baltz, MD

Psychiatry · Jonesboro, ARNPI 1194753046

Payments from drug & device makers

$1,311in general payments, 2019–2025

Across 99 payments — averaging $13.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$225
  • Vanda Pharmaceuticals Inc.$204
  • Otsuka America Pharmaceutical, Inc.$176
  • Sunovion Pharmaceuticals Inc.$157
  • Teva Pharmaceuticals USA, Inc.$154
  • Lundbeck LLC$115
  • plus $280 from 5 others

What the payments were for

  • Food & beverage$1,19991%
  • Education$1119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,311 in reported general payments places this provider in the 70th percentile of 235 psychiatry providers in Arkansas.

See all psychiatry providers in Arkansas

Medicare billing

Part B allowed, 2024
$73,359
Medicare patients
115
Services billed
1,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate54$457,272
Invega SustennaPaliperidone Palmitate74$231,877
Invega TrinzaPaliperidone Palmitate18$169,490
Abilify MaintenaAripiprazole31$88,256
AristadaAripiprazole Lauroxil18$60,626
RexultiBrexpiprazole40$60,413
Risperdal ConstaRisperidone Microspheres24$42,202
VraylarCariprazine Hcl28$39,548
CaplytaLumateperone Tosylate11$17,294
Chlorpromazine Hcl31$16,452
Aripiprazole173$15,290
Paliperidone ErPaliperidone38$7,787
TrintellixVortioxetine Hydrobromide14$7,084
Quetiapine Fumarate344$6,255
Divalproex Sodium133$5,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$87$457,27254 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$52$443,569116 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$176$148,66971 claims
Alkermes, Inc.Aristada$225$60,62618 claims
AbbVieVraylar$105$39,54828 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$24$17,29411 claims
Teva Pharmaceuticals USA, Inc.Loxapine$154$2,17519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 235 psychiatry providers in Arkansas.

Other psychiatry in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →